- Biotechnology company in clinical phase Molecular Partners (NASDAQ:CLOUD) and Orano Med, a radiopharmaceutical company in the clinical phase expand their strategic collaboration.
- The terms of the new agreement include the development of six additional targeted alpha therapeutic candidates, now representing a total of ten potential candidates.